Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Roisín M. Connolly(Johns Hopkins University), Vered Stearns(Johns Hopkins University), Richard L. Wahl(Mallinckrodt (United States)), Jennifer M. Specht(University of Washington), Antonio C. Wolff(Johns Hopkins University), Minetta C. Liu(Mayo Clinic), Ian E. Krop(Yale Cancer Center), Ashley Carpenter(National Cancer Institute), Ashley Cimino‐Mathews(Bloomberg (United States)), Lisa A. Carey(University of North Carolina at Chapel Hill), Anna Maria Storniolo(Indiana University Health), Christos Vaklavas(University of Alabama at Birmingham), Eric P. Winer(University of Vermont), Mothaffar F. Rimawi(Baylor College of Medicine), Chiung‐Yu Huang, Vandana G. Abramson(Vanderbilt University), Vicente Valero(The University of Texas MD Anderson Cancer Center), Ben Ho Park(Vanderbilt University Medical Center), Melissa Camp(Johns Hopkins University), Robert S. Miller(American Society of Clinical Oncology), Jeffrey P. Leal(Johns Hopkins University), Lilja B. Sólnes(Johns Hopkins University)
Cited by 46
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
|Science|2006|3.2k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k